David Liu

David Liu, PhD, is a Senior Analyst at Velan Capital Investment Management LP, a healthcare-dedicated investment firm, where he specializes in identifying and evaluating investment opportunities within the biopharmaceutical and biotechnology sectors. Based in New York, he plays a key role in Velan's research and portfolio management, with a specific focus on small and mid-cap therapeutics companies. His work is recognized for its depth in the evaluation of drug development pipelines and emerging therapeutic modalities.

Dr. Liu brings over 10 years of experience in healthcare and life sciences investing, having previously held roles as a Biotech Analyst at Altium Capital and as Senior Analyst at Iguana Healthcare. He began his career as an equity research associate covering biotechnology at RBC Capital Markets, building expertise in both private and public equity research within the healthcare industry.

He holds a BS in Biological Sciences from Stanford University and earned his PhD in Molecular Biology from Weill Cornell Graduate School of Medical Sciences, with thesis research conducted at Memorial Sloan Kettering Cancer Center. Dr. Liu is also a board director at Edesa Biotech, Inc., where his expertise in the biopharmaceutical industry and investment acumen contribute to corporate strategy and capital allocation decisions.